Biotech Values

[DewDiligence]

CMPS IPOs 8.63M* ADSs @$17.00:

https://www.globenewswire.com/news-release/2020/09/18/2095607/0/en/COMPASS-Pathways-announces-pricing-of-upsized-initial-public-offering.html

COMPASS Pathways plc is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.

…We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA.

*Assuming exercise of underwriter’s option.